We write regarding enforcement of North Carolina’s state law that requires insurers to count copay assistance from drug manufacturers towards beneficiaries’ cost-sharing obligations. As detailed in the letter, Mr. Frank Marino has an Ambetter plan that, contrary to state law, is not counting his copay assistance towards his deductible. According to him, the NC Insurance Department has interpreted the law in a contrary manner. As noted in the letter, United Healthcare also has language in their plan policy documents stating that copay assistance does not count. We are asking you to review these matters and fully enforce the law. Additionally, we would very much like to meet with you at your earliest convenience.
Comments to the Oregon PDAB on PBM Practices and Continuity of Care
We strongly support the Board’s recommendation to strengthen PBM oversight through standardized financial reporting, disclosure of affiliated businesses, independent audit authority, and greater public transparency. PBMs play a significant role in determining which medications patients can access and how much they pay at the pharmacy counter. Yet complex financial arrangements make it difficult to determine whether negotiated rebates and discounts ultimately benefit patients.
Comments to the FTC supporting and offering recommendations on proposed order and settlement with Caremark Rx L.L.C. and Zinc Health Services L.L.C.
We write to express our support for the proposed settlement with with Caremark Rx, L.L.C. and Zinc Health Services, LLC to highlight several provisions that will significantly improve affordability and access to medications for patients and propose critical enhancements to further strengthen the order’s protections.
Letter to PCMA on patient protections in their TrumpRx price comparisons
HIV+Hepatitis Policy Institute and the Arthritis Foundation sent a letter to PCMA raising concerns about how its members will present TrumpRx prices to insured patients. The groups urged PCMA members to clearly disclose whether TrumpRx purchases will count toward patients’ deductibles and out-of-pocket maximums, warning that a lower cash price today could ultimately result in higher costs over the course of the plan year.
Testimony for ad hoc HIV/AIDS interim meeting Medicaid Pharmaceutical & Therapeutics Committee Connecticut Division of Health Services
Though Connecticut’s statutory exclusion of antiretrovirals from the Medicaid Preferred Drug List has ended, we continue to oppose adding any antiretrovirals for HIV treatment or prevention to the PDL with non-preferred status, which would enable prior authorization and step therapy on those drugs.